Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® ...

Company Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...

Detailed price information for Actuate Therapeutics Inc (ACTU-Q) from The Globe and Mail including charting and trades.

The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma Eligible ...

Epcoritamab monotherapy achieved high overall (84.6%) and complete response rates (67.1%) in relapsed/refractory follicular lymphoma patients with multiple prior therapies. Combination therapy with ...

QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...

A new update from the American Gastroenterological Association (AGA) is calling for greater caution before surgery is ...

Chronic constipation affects 8–12% of Americans. While most patients improve with conventional treatments, a small but ...